J&J keeping Remicade biosimilars at bay through price drops
Johnson & Johnson’s Remicade continues to hold 92% of the market by volume three years since infliximab biosimilars arrived in the US. Johnson & Johnson (J&J) opened the first quarter 2019 reporting season this week by announcing an 8% year-on-year growth in its pharmaceutical’s d ...
An agreement between Novasep and Theravectys gives the French CDMO access to the Institut Pasteur's DNA FLAP technology to produce GMP-grade lent ...
Fresh from an acquisition agreement by Catalent, Paragon Bioservices is seeking to establish a second manufacturing plant dedicated to produce Sa ...
Seqirus’s vaccine offering for the 2019/20 season will be uniquely cell-base, but the firm says traditional egg-based production still plays a ...
Allele Biotechnology has teamed with SCM Lifescience to develop diabetes therapies using pancreatic beta cells derived from induced pluripotent s ...
Recent Tweets
-
RT @Dan5tanton: The US Biomedical Advanced Research and Development Authority ( #BARDA ) will use Enesi Pharma’s ImplaVax device an… https://t.co/v6XhAo33hk
6 days ago
-
BREAKING NEWS - more consolidation in gene therapy CMO space https://t.co/DCz8eUuaTQ
7 days ago
-
Cell therapy vendors: News from Miltenyi, Saint-Gobain, Bellicum and HCATS #CDMO #celltherapy… https://t.co/Y2ya0CwjO2
1 week ago
-
RT @Dan5tanton: Russian biopharma Generium has launched Elizaria, a #biosimilar version of Alexion’s blockbuster MAb Soliris (eculi… https://t.co/eoDR7oqkgp
1 week ago
Trending
Upstream Processing
Monoclonal Antibodies: Beyond the Platform in Manufacturing
2019
2019 BioProcess International West Event Report
Analytical Upstream Processing
Visible Particulate Matter in Single-Use Bags: From Measurement to Prevention
Manufacturing
Is the QbD Toolbox Ready for Cell and Gene Therapies? Integrating Patient Outcomes into Manufacturing Cell and Gene Therapy Bioproducts